Guggenheim initiated coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research note released on Monday, BenzingaRatingsTable reports. The brokerage issued a buy rating on the stock.
A number of other equities analysts also recently issued reports on the stock. Royal Bank of Canada assumed coverage on shares of Genmab A/S in a research note on Monday. They issued an outperform rating and a $23.00 price target for the company. Morgan Stanley assumed coverage on shares of Genmab A/S in a research note on Monday. They issued an overweight rating for the company.
GMAB stock opened at $19.89 on Monday. Genmab A/S has a 1 year low of $12.10 and a 1 year high of $21.45.
An institutional investor recently bought a new position in Genmab A/S stock. Parametric Portfolio Associates LLC purchased a new position in Genmab A/S (NASDAQ:GMAB) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 375,476 shares of the company’s stock, valued at approximately $6,937,000. Parametric Portfolio Associates LLC owned 0.29% of Genmab A/S at the end of the most recent quarter. 0.80% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Article: Candlestick
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.